title: Pretargeting with the affinity enhancement system for radioimmunotherapy.
abstract: The pretargeting technique referred to as the Affinity Enhancement System (AES) uses bispecific antibodies and radiolabeled bivalent haptens that bind cooperatively to target cells in vivo. Experimental and clinical data demonstrate that AES can deliver large radiation doses to tumor cells with high tumor to normal tissue contrast ratios and long activity residence time in tumors. Preliminary clinical results of radioimmunotherapy of medullary thyroid carcinomas and lung cancers look promising.
authors.affiliation: INSERM Research Unit 463, Nantes, France.
authors.forename: J
authors.initials: J
authors.lastname: Barbet
authors.forename: F
authors.initials: F
authors.lastname: Kraeber-Bodéré
authors.forename: J P
authors.initials: JP
authors.lastname: Vuillez
authors.forename: E
authors.initials: E
authors.lastname: Gautherot
authors.forename: E
authors.initials: E
authors.lastname: Rouvier
authors.forename: J F
authors.initials: JF
authors.lastname: Chatal
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000493:pharmacokinetics / Q000627:therapeutic use; D018276:Carcinoma, Medullary / Q000000981:diagnostic imaging / Q000532:radiotherapy; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D016719:Radioimmunodetection; D016499:Radioimmunotherapy / Q000379:methods*; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy
chemical_list: D018033:Antibodies, Bispecific